Reports of the death of CB1 antagonists have been greatly exaggerated: Recent preclinical findings predict improved safety in the treatment of obesity

Behavioural Pharmacology

Volumn 23, Issue 5-6, 2012, Pages 537-550

  McLaughlin, Peter J ^a  

^a EDINBORO UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Appetite suppressant drugs; cannabinoids; drug antagonism; drug inverse agonism; food intake; laboratory animal models; motivation; new drug approval; rimonabant

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 8 BROMO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL; AMPHETAMINE; DEXFENFLURAMINE; DRINABANT; FENFLURAMINE; PHENTERMINE; RIMONABANT; SIBUTRAMINE; TARANABANT; TETRAHYDROLIPSTATIN;

ANXIETY DISORDER; APPETITE; DEPRESSION; DIABETES MELLITUS; DISEASE MODEL; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; HUMAN; HYPOPHAGIA; LIPOGENESIS; META ANALYSIS (TOPIC); NAUSEA; NONHUMAN; OBESITY; PREDICTION; PRURITUS; REVIEW; SEIZURE; UNITED STATES;

ANIMALS; ANXIETY; APPETITE DEPRESSANTS; APPETITE STIMULANTS; CANNABINOID RECEPTOR ANTAGONISTS; DEPRESSION; DRUG INVERSE AGONISM; ENDOCANNABINOIDS; HUMANS; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; NEURONS; OBESITY; PERIPHERAL NERVES; RECEPTOR, CANNABINOID, CB1; SEIZURES;

EID: 84864869951     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283566a8c     Document Type: Review

References (177)

1. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, et al. (2008). The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7:68-78.
2. Arnone M, Maruani J, Frédérique C, Thiébot MH, Poncelet M, Soubrié P, Le Fur G (1997). Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 132:104-106.
3. Aronne LJ, Tonstad S, Moreno M, Gantz I, Erondu N, Suryawanshi S, et al. (2010). A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high dose study. Int J Obes 34:919-935.
4. Bambico FR, Katz N, Debonnel G, Gobbi G (2007). Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 27:11700-11711.
5. Beardsley PM, Dance ME, Balster RL, Munzar P (2002). Evaluation of the reinforcing effects of the cannabinoid CB1 receptor antagonist, SR141716, in rhesus monkeys. Eur J Pharmacol 435:209-216.
6. Bergman J, Delatte MS, Paronis CA, Vemuri K, Thakur GA, Makriyannis A (2008). Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. Physiol Behav 93:666-670.
7. Berrendero F, Maldonado R (2002). Involvement of the opioid system in the anxiolytic-like effects induced by d9-tetrahydrocannabinol. Psychopharmacology (Berl) 163:111-117.
8. Berridge KC, Aldridge JW (2000). Super-stereotypy I: enhancement of a complex movement sequence by systemic dopamine D1 agonists. Synapse 37: 194-204.
9. Beyer CE, Dwyer JM, Piesla MJ, Platt BJ, Shen R, Rahman Z, et al. (2010). Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol Dis 39:148-155.
10. Black MD, Stevens RJ, Rogacki N, Featherstone RE, Senyah Y, Giardino O, et al. (2011). AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl) 215:149-163.
11. Bourin M, Fiocco AJ, Clenet F (2001). How valuable are animal models in defining antidepressant activity? Hum Psychopharmacol 16:9-21.
12. Canals M, Milligan G (2008). Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors. J Biol Chem 283:11424-11434.
13. Chait LD, Uhlenhuth EH, Johanson CE (1987). Reinforcing and subjective effects of several anorectics in normal human volunteers. J Pharmacol Exp Ther 242:777-783.
14. Chambers AP, Koopmans HS, Pittman QJ, Sharkey KA (2006). AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion. Br J Pharmacol 147:109-116.
15. Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ, et al. (2007). A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 293:R2185-R2193.
16. Chen RZ, Frassetto A, Lao JZ, Huang RR, Xiao JC, Clements MJ, et al. (2008). Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor. Eur J Pharmacol 584:338-342.
17. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706-1713.
18. Cluny NL, Vemuri VK, Chambers AP, Limebeer CL, Bedard H, Wood JT, et al. (2010). A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 161:629-642.
19. Cluny NL, Chambers AP, Vemuri VK,Wood JT, Eller LK, Freni C, et al. (2011). The neutral cannabinoid CB1 receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol Biochem Behav 97:537-543.
20. Colman E (2005). Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med 143:380-385.
21. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998). Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63:113-117.
22. Colombo G, Orrù A, Lai P, Cabras C, Maccioni P, Rubio M, et al. (2007). The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence. Mol Neurobiol 36:102-112.
23. Compton DR, Aceto MD, Lowe J, Martin BR (1996). In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586-594.
24. Costa B, Colleoni M (1999). SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists. Acta Pharmacol Sin 20: 1103-1108.
25. Cota D, Marsicano G, Tschöp M, Grü bler Y, Flachskamm C, Schubert M, et al. (2003). The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112: 423-431.
26. Croci T, Manara L, Aureggi G, Guagnini F, Rinaldi-Carmona M, Maffrand JP, et al. (1998). In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol 125:1393-1395.
27. Darmani NA (2001). Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24:198-203.
28. Darmani NA, Pandya DK (2000). Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice. J Neural Transm 107:931-945.
29. Davis JD, Levine MW (1977). A model for the control of ingestion. Psychol Rev 84:379-412.
30. Degroot A, Nomikos GG (2004). Genetic deletion and pharmacological blockade of CB1 receptors modulates anxiety in the shock-probe burying test. Eur J Neurosci 20:1059-1064.
31. De Vry J, Schreiber R, Eckel G, Jentzsch KR (2004). Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR 141716A. Eur J Pharmacol 483: 55-63.
32. Deshpande LS, Sombati S, Blair RE, Carter DS, Martin BR, DeLorenzo RJ (2007). Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy. Neurosci Lett 411:11-16.
33. Despré s JP, Golay A, Sjö ström L (2005). Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353: 2121-2134.
34. Despré s JP, Ross R, Boka G, Almé ras N, Lemieux I (2009). Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 29:416-423.
35. Di Marzo V, Goparaju SK, Wang L, Liu J, Bá tkal S, Já ral Z, et al. (2001). Leptinregulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825.
36. DiPatrizio NV, Simansky KJ (2008). Activating parabrachial cannabinoid CB1 receptors selectively stimulates feeding of palatable foods in rats. J Neurosci 28:9702-9709.
37. DiPatrizio NV, Astarita G, Schwartz G, Li X, Piomelli D (2011). Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci USA 108:12904-12908.
38. Doremus TL, Varlinskaya EI, Spear LP (2004). Age-related differences in elevated plus maze behavior between adolescent and adult rats. Ann NY Acad Sci 1021:427-430.
39. Eisenstein SA, Holmes PV, Hohmann AG (2009). Endocannabinoid modulation of amphetamine sensitization is disrupted in a rodent model of lesion-induced dopamine dysregulation. Synapse 63:941-950.
40. Eisenstein SA, Clapper JR, Holmes PV, Piomelli D, Hohmann AG (2010). A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy. Pharmacol Res 61:419-429.
41. Erdozain AM, Diez-Alarcia R, Meana JJ, Callado LF (2012). The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain. Biochem Pharmacol 83:260-268.
42. Escartín-Pé rez RE, Cendejas-Trejo NM, Cruz-Martínez AM, Gonzá lez-Hernández B, Mancilla-Díaz JM, Florán-Garduño B (2008). Role of cannabinoid CB1 receptors on macronutrient selection and satiety in rats. Eur J Pharmacol 96:646-650.
43. European Medicines Agency (EMEA) (2008). The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. Press release 23 October 2008.
44. Foltin RW, Brady JV, Fischman MW (1986). Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav 25:577-582.
45. Food and Drug Administration, Endocrine and Metabolic Drugs Advisory Committee (2007). FDA briefing document NDA 21-888 Zimulti (rimonabant). Available at: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-fda- backgrounder.pdf. [Accessed 7 January 2012].
46. Freedland CS, Poston JS, Porrino LJ (2000). Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol Biochem Behav 67:265-270.
47. Gardner A, Mallet PE (2006). Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. Eur J Pharmacol 530:103-106.
48. Giraldo J (2010). How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue. Drug Discov Today 15:411-415.
49. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, et al. (2005). Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102:18620-18625.
50. Gómez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, et al. (2002). A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22:9612-9617.
51. Griebel G, Stemmelin J, Scatton B (2005). Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 57:261-267.
52. Halford JCG, Wanninayake SCD, Blundell JE (1998). Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 61:159-168.
53. Harrold JA, Elliott JC, King PJ, Widdowson PS, Williams G (2002). Downregulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Res 952:232-238.
54. Hart CL, Ward AS, Haney M, Comer SD, Foltin RW, Fischman MW (2002). Comparison of smoked marijuana and oral D9-tetrahydrocannabinol in humans. Psychopharmacology (Berl) 164:407-415.
55. Higgs S, Williams CM, Kirkham TC (2003). Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after D9-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR 141716. Psychopharmacology (Berl) 165:370-377.
56. Higuchi S, Irie K, Mishima S, Araki M, Ohji M, Shirakawa A, et al. (2010). The cannabinoid 1-receptor silent antagonist O-2050 attenuates preference for high-fat diet and activated astrocytes in mice. J Pharmacol Sci 112: 369-372.
57. Hildebrandt AL, Kelly-Sullivan DM, Black SC (2003). Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 462:125-132.
58. Hill AJ,Weston SE, Jones NA, Smith I, Bevan SA, Williamson EM, et al. (2010). D9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia 51:1522-1532.
59. Hodge J, Bow JP, Plyler KS, Vemuri VK,Wisniecki A, Salamone JD, et al. (2008). The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats. Behav Brain Res 193:298-305.
60. Hogg S (1996). A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav 54:21-30.
61. Hohmann AG, Herkenham M (1999). Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 90: 923-931.
62. Hopkins ME, Bucci DJ (2010). Interpreting the effects of exercise on fear conditioning: the influence of time of day. Behav Neurosci 124:868-872.
63. Horswill JG, Bali U, Shaaban S, Keily JF, Jeevaratnam P, Babbs AJ, et al. (2007). PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol 152:805-814.
64. Hortala L, Rinaldi-Carmona M, Congy C, Boulu L, Sadoun F, Fabre G, et al. (2010). Rational design of a novel peripherally-restricted, orally active CB(1) cannabinoid antagonist containing a 2,3-diarylpyrrole motif. Bioorg Med Chem Lett 20:4573-4577.
65. Huang P, Liu-Chen LY, Kirby LG (2010). Anxiety-like effects of SR141716-precipitated delta9-tetrahydrocannabinol withdrawal in mice in the elevated plus-maze. Neurosci Lett 475:165-168.
66. Hudson BD, Hé bert TE, Kelly ME (2010). Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors. Br J Pharmacol 160:627-642.
67. Hungund BL, Vinod KY, Kassir SA, Basavarajappa BS, Yalamanchili R, Cooper TB, et al. (2004). Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 9:184-190.
68. Jamshidi N, Taylor DA (2001). Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 134:1151-1154.
69. Järbe TU, Ross T, DiPatrizio NV, Pandarinathan L, Makriyannis A (2006). Effects of the CB1R agonist WIN-55212-2 and the CB1R antagonist SR-141716 and AM-1387: open-field examination in rats. Pharmacol Biochem Behav 85:243-252.
70. Järbe TUC, LeMay BJ, Olszewska T, Vemuri VK,Wood JT, Makriyannis A (2008). Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats. Pharmacol Biochem Behav 91:84-90.
71. Jarrett MM, Limebeer CL, Parker LA (2005). Effect of D9- tetrahydrocannabinol on sucrose palatability as measured by the taste reactivity test. Physiol Behav 86:475-479.
72. Jewett D, Hahn T, Smith T, Fiksdal B, Wiebelhaus J, Dunbar A, et al. (2009). Effects of sibutramine and rimonabant in rats trained to discriminate between 22-and 2-h food deprivation. Psychopharmacology (Berl) 203:453-459.
73. Johansson K, Neovius K, DeSantis SM, Rö ssner S, Neovius M (2009). Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev 10:564-575.
74. Johansson K, Sundström J, Neovius K, Rö ssner S, Neovius M (2010). Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Obes Rev 11:777-791.
75. Jones D (2008). End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov 7:961-962.
76. Jutkiewicz EM, Makriyannis A, Vemuri K, Bergman J (2010). Pro-depressant-like effects of CB1 receptor inverse agonists/antagonists in male Sprague-Dawley rats. FASEB J 24:7.
77. Kim M, Yun H, Kwak H, Kim J, Lee J (2008). Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist. Tetrahedron 64:10802-10809.
78. Kinsey SG, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH (2011). Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav 98:21-27.
79. Kirkham TC,Williams CM, Fezza F, Di Marzo V (2002). Endocannabinoid levels in rat forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136: 550-557.
80. Koch JE (2001). D9-THC stimulates food intake in Lewis rats: effects on chow, high-fat and sweet high-fat diets. Pharmacol Biochem Behav 68:539-543.
81. Kola B, Farkas I, Christ-Crain M, Wittmann G, Lolli F, Amin F, et al. (2008). The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One 3:e1797.
82. Kozan R, Ayyildiz M, Agar E (2009). The effects of intracerebroventricular AM-251, a CB1-receptor antagonist, and ACEA, a CB1-receptor agonist, on penicillin-induced epileptiform activity in rats. Epilepsia 50:1760-1767.
83. Krauskopf L (2008). Merck ends development of obesity drug taranabant. Reuters. Available at: http://www.reuters.com/article/2008/10/02/ merckidUSN0224498220081002. [Accessed 12 January 2012].
84. Lamota L, Bermudez-Silva FJ, Marco EM, Llorente R, Gallego A, Rodríguez de Fonseca F, Viveros MP (2008). Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats. Neuropharmacology 54:195-205.
85. Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI (1997). SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 334:R1-R2.
86. Le Foll B, Goldberg SR (2005). Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 312:875-883.
87. Le Foll B, Gorelick DA, Goldberg SR (2009). The future of endocannabinoidoriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 205:171-174.
88. Lichtman AH (2000). SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. Eur J Pharmacol 404:175-179.
89. Limebeer CL, Vemuri VK, Bedard H, Lang ST, Ossenkopp KP, Makriyannis A, Parker LA (2010). Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. Br J Pharmacol 161:336-349.
90. LoVerme J, Duranti A, Tontini A, Spadoni G, Mor M, Rivara S, et al. (2009). Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduced feeding and body-weight gain in mice. Bioorg Med Chem Lett 19:639-643.
91. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BWJH, Zitman FG (2010). Overweight, obesity, and depression: a systematic review and metaanalysis of longitudinal studies. Arch Gen Psychiatry 67:220-229.
92. Lyte M, Opitz N, Goehler LE, Gaykema RP, Overmier JB (2005). Recommended housing conditions and test procedures can interact to obscure a significant experimental effect. Behav Res Methods 37:651-656.
93. Maccioni P, Pes D, Carai MAM, Gessa GL, Colombo G (2008). Suppression by the cannabinoid CB1 receptor antagonist, rimonabant, of the reinforcing and motivational properties of a chocolate-flavoured beverage in rats. Behav Pharmacol 19:197-209.
94. MacLennan SJ, Reynen PH, Kwan J, Bonhaus DW (1998). Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br J Pharmacol 124:619-622.
95. Madsen AN, Jelsing J, van de Wall EHEM, Vrang N, Larsen PJ, Schwartz GJ (2009). Rimonabant induced anorexia in rodents is not mediated by vagal or sympathetic gut afferents. Neurosci Lett 449:20-23.
96. Makwana R, Molleman A, Parsons ME (2010). Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation. Br J Pharmacol 160:615-626.
97. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530-534.
98. McLaughlin PJ,Winston KM, Swezey LA,Wisniecki A, Aberman J, Tardif DJ, et al. (2003). The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 14:583-588.
99. McLaughlin PJ, Lu D, Winston KM, Thakur GA, Swezey LA, Makriyannis A, Salamone JD (2005a). Behavioral effects of the novel cannabinoid full agonist AM411. Pharmacol Biochem Behav 81:78-88.
100. McLaughlin PJ, Winston KM, Limebeer CL, Parker LA, Makriyannis A, Salamone JD (2005b). The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology (Berl) 180:286-293.
101. McLaughlin PJ, Qian L, Wood JT, Wisniecki A, Winston KM, Swezey LA, et al. (2006). Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387. Pharmacol Biochem Behav 83:396-402.
102. McLaughlin PJ, Winston KM, Swezey LA, Makriyannis A, Salamone JD (2010). Detailed analysis of food-reinforced operant lever pressing distinguishes effects of a cannabinoid CB1 inverse agonist and dopamine D1 and D2 antagonists. Pharmacol Biochem Behav 96:75-81.
103. Monteleone P, Bifulco M, Maina G, Tortorella A, Gazzerro P, Proto MC, et al. (2010). Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol Res 61: 400-404.
104. Naderi N, Aziz Ahari F, Shafaghi B, Najarkolaei AH, Motamedi F (2008). Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice. J Neural Transm 115: 1501-1511.
105. Navarro M, Hernández E, Muñ oz RM, del Arco I, Villanú a MA, Carrera MRA, Rodríguez de Fonseca F (1997). Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8:491-496.
106. Pagano C, Rossato M, Vettor R (2008). Endocannabinoids, adipose tissue and lipid metabolism. J Neuroendocrinol 20:124-129.
107. Pagotto U, Cervino C, Vicennati V, Marsicano G, Lutz B, Pasquali R (2005). How many sites of action for endocannabinoids to control energy metabolism? Int J Obes (Lond) 30:S39-S43.
108. Parker LA (2003). Taste avoidance and taste aversion: evidence for two different processes. Learn Behav 31:165-172.
109. Parker LA, Mechoulam R (2003). Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. Integr Psychol Behav Sci 38:133-145.
110. Parker LA, Kwiatkowska M, Burton P, Mechoulam R (2004). Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) 171:156-161.
111. Patel S, Hillard CJ (2006). Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318: 304-311.
112. Pavó n FJ, Bilbao A, Hernández-Folgado L, Cippitelli A, Jagerovic N, Abellán G, et al (2006). Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-3-hexyl-1H-1,2,4-triazole-LH 21. Neuropharmacology 51: 358-366.
113. Pavón FJ, Serrano A, Pérez-Valero V, Jagerovic N, Hernández-Folgado L, Bermúdez-Silva J, et al. (2008) Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J Neuroendocrinol 20: 116-123.
114. Pé rio A, Barnouin MC, Poncelet M, Soubrié P (2001). Activity of SR141716 on post-reinforcement pauses in operant responding for sucrose reward in rats. Behav Pharmacol 12:641-645.
115. Pertwee RG (2005). Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307-1324.
116. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J (2006). Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 201:761-775.
117. Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE, et al. (2005). The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 7:65-72.
118. Proietto J, Rissanen A, Harp JB, Erondu N, Yu Q, Suryawanashi S, et al. (2010). A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. Int J Obes 34:1243-1254.
119. Randall PA, Vemuri VK, Segovia KN, Ferreris Torres E, Hosmer S, Nunes EJ, et al. (2010). The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol Biochem Behav 97: 179-184.
120. Rasmussen EB, Huskinson SL (2008). Effects of rimonabant on behavior maintained by progressive ratio schedules of sucrose reinforcement in obese Zucker (fa/fa) rats. Behav Pharmacol 19:735-742.
121. Ray AP, Griggs L, Darmani NA (2009). Delta 9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew. Behav Brain Res 196:30-36.
122. Rinaldi-Carmona M, Francis B, Hé aulme M, Shire D, Calandra B, Congy C, et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
123. Rodgers RJ, Haller J, Halasz J, Mikics E (2003). 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur J Neurosci 17:1279-1286.
124. Rodgers RJ, Evans PM, Murphy A (2005). Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-na?̈ve and plusmaze-experienced mice. Behav Pharmacol 16:405-413.
125. Rodríguez-Gaztelumendi A, Rojo ML, Pazos A, Díaz A (2009). Altered CB1 receptor-signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine. J Neurochem 108:1423-1433.
126. Rubino T, Guidali C, Vigano D, Realini N, Valenti M, Massi P, Parolaro D (2008). CB1 receptor stimulation in specific brain areas differently modulate anxietyrelated behaviour. Neuropharmacology 54:151-160.
127. Rumsfeld JS, Nallamothu BK (2008). The hope and fear of rimonabant. JAMA 299:1601-1602.
128. Salamone JD, Steinpreis RE, McCullough LD, Smith P, Grebel D, Mahan K (1991). Haloperidol and nucleus accumbens dopamine depletion suppress lever pressing for food but increase free food consumption in a novel food choice procedure. Psychopharmacology (Berl) 104:515-521.
129. Scheen AJ (2008). CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. J Neuroendocrinol 20:139-146.
130. Scheen AJ (2010). Cardiovascular risk-benefit profile of sibutramine. Am J Cardiovasc Drugs 10:321-334.
131. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF (2006). Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 368:1660-1672.
132. Schlosburg JE, O'Neal ST, Conrad DH, Lichtman AH (2011). CB1 receptors mediate rimonabant-induced pruritic responses in mice: Investigation of locus of action. Psychopharmacology (Berl) 216:323-331.
133. Schramm-Sapyta NL, Cha YM, Chaudhry S,Wilson WA, Swartzwelder HS, Kuhn CM (2007). Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. Psychopharmacology (Berl) 191:867-877.
134. Schuh LM, Schuster CR, Hopper JA, Mendel CM (2000). Abuse liability assessment of sibutramine, a novel weight control agent. Psychopharmacology (Berl) 147:339-346.
135. Sciolino NR, Zhou W, Hohmann AG (2011). Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol Res 64:226-234.
136. Serra G, Fratta W (2007). A possible role for the endocannabinoid system in the neurobiology of depression. Clin Pract Epidemiol Ment Health 3:25.
137. Shubina LV, Kichigina VF (2011). Protective effects of CB1 receptor agonistWIN 55.212-2 in seizure activity in the model of temporal lobe epilepsy. Zh Vyssh Nerv Deiat Im I P Pavlova 61:94-101.
138. Simiand J, Keane M, Keane PE, Soubrié P (1998). SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 9:179-181.
139. Simoneau II, Hamza MS, Mata HP, Siegel EM, Vanderah TW, Porreca F, et al. (2001). The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology 94:882-887.
140. Sink KS, McLaughlin PJ,Wood JT, Brown CM, Fan P, Vemuri VK, et al. (2007). The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 33:946-955.
141. Sink KS, Vemuri VK, Olszewska T, Makriyannis A, Salamone JD (2008a). Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior. Psychopharmacology (Berl) 196:565-574.
142. Sink KS, Vemuri VK, Wood JT, Makriyannis A, Salamone JD (2008b). Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113. Pharmacol Biochem Behav 91:303-306.
143. Sink KS, Segovia KN, Nunes EJ, Collins LE, Vemuri VK, Thakur GA, et al. (2009). Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats. Psychopharmacology (Berl) 206:223-232.
144. Sink KS, Segovia KN, Collins LE, Markus EJ, Vemuri VK, Makriyannis A, Salamone JD (2010a). The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats. Pharmacol Biochem Behav 95:479-484.
145. Sink KS, Segovia KN, Sink J, Randall PA, Collins LE, Correa M, et al. (2010b). Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol 20: 112-122.
146. Sofia RD, Knobloch LC (1976). Comparative effects of various naturally occurring cannabinoids on food, sucrose and water consumption by rats. Pharmacol Biochem Behav 4:591-599.
147. Tadaiesky MT, Dombrowski PA, Da Cunha C, Takahashi RN (2010). Effects of SR141716A on cognitive and depression-related behavior in an animal model of premotor Parkinson's Disease. Parkinsons Dis 2010:238491.
148. Takahashi E, Katayama M, Niimi K, Itakura C (2008). Additive subthreshold dose effects of cannabinoid CB(1) receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests. Eur J Pharmacol 589:149-156.
149. Tallett AJ, Blundell JE, Rodgers JR (2007a). Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation. Behav Pharmacol 18:591-600.
150. Tallett AJ, Blundell JE, Rodgers JR (2007b). Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats. Psychopharmacology (Berl) 195:27-39.
151. Tam J, Vemuri VK, Liu J, Bá tkai S, Mukhopadhyay B, Godlewski G, et al. (2010). Peripheral CB1 cannabinoid receptor blockage improves cardiometabolic risk in mouse models of obesity. J Clin Invest 120:2953-2966.
152. Thornton-Jones ZD, Kennett GA, Vickers SP, Clifton PG (2007). A comparison of the effects of the CB1 receptor antagonist SR141716A, pre-feeding and changed palatability on the microstructure of ingestive behaviour. Psychopharmacology (Berl) 193:1-9.
153. Topol EJ, Bousser MG, Fox KAA, Creager MA, Despré s JP, Easton JD, et al. (2010). Rimonabant for prevention of cardiovascular events (CRESCENDO): a ransomised, multicenter, placebo-controlled trial. Lancet 376:517-523.
154. Van Gaal L, Pi-Sunyer X, Despré s JP, McCarthy C, Scheen A (2008).
155. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397.
156. Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA (2003). D9-Tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285:G566-G576.
157. Verty ANA, Singh ME, McGregor IS, Mallet PE (2003). The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine. Psychopharmacology (Berl) 168:314-323.
158. Verty ANA, McGregor IS, Mallet PE (2004). Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci Lett 354:217-220.
159. Verty ANA, McGregor IS, Mallet PE (2005). Paraventricular hypothalamic CB(1) cannabinoid receptors are involved in the feeding stimulatory effects of Delta(9)-tetrahydrocannabinol. Neuropharmacology 49:1101-1109.
160. Verty ANA, Boon WM, Mallet PE, McGregor IS, Oldfield BJ (2009). Involvement of hypothalamic peptides in the anorectic action of the CB receptor antagonist rimonabant (SR 141716). Eur J Neurosci 29:2207-2216.
161. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA (2003). Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 167:103-111.
162. Vinod KY, Arango V, Xie S, Kassir SA, Mann JJ, Cooper TB, Hungund BL (2005). Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol Psychiatry 57:480-486.
163. Vinogradova LV, Shatskova AB, van Rijn CM (2011). Pro-epileptic effects of the cannabinoid receptor antagonist SR141716 in a model of audiogenic epilepsy. Epilepsy Res 96:250-256.
164. Wallace MJ,Wiley JL, Martin BR, DeLorenzo RJ (2001). Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol 428:51-57.
165. Wallace MJ, Martin BR, DeLorenzo RJ (2002). Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol 452:295-301.
166. Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ (2003). The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 307:129-137.
167. Wang X, Horswill JG, Whalley BJ, Stephens GJ (2011). Effects of the allosteric antagonist 1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl) phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum. Mol Pharmacol 79:758-767.
168. Ward SJ, Dykstra LA (2005). The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav Pharmacol 16:381-388.
169. Ward SJ, Lefever TW, Jackson C, Tallarida RJ, Walker EA (2008). Effects of a Cannabinoid1 receptor antagonist and Serotonin2C receptor agonist alone and in combination on motivation for palatable food: a dose-addition analysis study in mice. J Pharmacol Exp Ther 325:567-576.
170. Werner NA, Koch JE (2003). Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats. Brain Res 967:290-292.
171. Wiley JL, Burston JJ, Leggett DC, Alekseeva OO, Razdan RK, Mahadevan A, Martin BR (2005). CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 145:293-300.
172. Wiley JL, Breivogel CS, Mahadevan A, Pertwee RG, Cascio MG, Bolognini D, et al. (2011). Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB1 receptor antagonist. Eur J Pharmacol 650:96-105.
173. Williams CM, Kirkham TC (1999). Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 143:315-317.
174. Williams CM, Kirkham TC (2002). Observational analysis of feeding induced by the D9-THC and anandamide. Physiol Behav 76:241-250.
175. Wolff MC, Leander JD (2003). SR141716A, a cannabinoid CB1 receptor antagonist, improves memory in a delayed radial maze task. Eur J Pharmacol 477:213-217.
176. Wu HM, Yang YM, Kim SG (2011). Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of Ga i/o inhibition. Mol Pharmacol 80:859-869.
177. Yamauchi T, Kamon J,Waki H, Terauchi Y, Kubota N, Hara K, et al. (2001). The fatderived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946.